Does Rallies show Form 4 insider transactions for VERA?

Yes. Rallies tracks VERA insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is VERA research on Rallies investment advice?

No. Rallies provides research, data, and educational context for VERA. It does not provide personalized investment advice.

VERA (Vera Therapeutics, Inc. Class A Common Stock) Stock Analysis - Insider Trades

Vera Therapeutics, Inc. Class A Common Stock (VERA) is a publicly traded Healthcare sector company. As of May 21, 2026, VERA trades at $34.67 with a market cap of $2.47B and a P/E ratio of -7.31. VERA moved +4.15% today. Year to date, VERA is -26.45%; over the trailing twelve months it is +62.99%. Its 52-week range spans $18.53 to $56.05. Analyst consensus is strong buy with an average price target of $77.67. Rallies surfaces VERA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading VERA stock inside the company?

Recent VERA insider activity includes Fordyce Marshall sold 14.22K, Fordyce Marshall sold 4.28K, Fordyce Marshall sold 14.13K, Fordyce Marshall sold 7.92K, and Fordyce Marshall sold 900. Rallies tracks insider transaction dates, shares, prices, and estimated values.

VERA Key Metrics

Key financial metrics for VERA
Metric	Value
Price	$34.67
Market Cap	$2.47B
P/E Ratio	-7.31
EPS	$-4.66
Dividend Yield	0.00%
52-Week High	$56.05
52-Week Low	$18.53
Volume	10
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-299.62M
Gross Margin	0.00%

Recent VERA Insider Trades

Fordyce Marshall sold 14.22K (~$520.98K) on May 12, 2026.
Fordyce Marshall sold 4.28K (~$158.77K) on May 12, 2026.
Fordyce Marshall sold 14.13K (~$616.99K) on Apr 14, 2026.
Fordyce Marshall sold 7.92K (~$353.11K) on Apr 14, 2026.
Fordyce Marshall sold 900 (~$40.96K) on Apr 14, 2026.

Latest VERA News

Vera Therapeutics Grants 40,250 Options and 20,125 RSUs at $35.51 Exercise Price — May 8, 2026
Vera Therapeutics Wins FDA Priority Review with July 7 PDUFA; Q1 Loss $121M — May 7, 2026
Vera Therapeutics grants 258,200 options, 131,925 RSUs at $40.33 to 89 hires — Apr 10, 2026
Vera Therapeutics Names Jane Wright-Mitchell as CLO Ahead of Atacicept Launch — Mar 25, 2026
Vera Therapeutics Grants 46,000 Options at $39.30 Strike to Six New Hires — Mar 6, 2026

VERA Analyst Consensus

9 analysts cover VERA: 0 strong buy, 8 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $77.67.

Common questions about VERA

Who is trading VERA stock inside the company?: Recent VERA insider activity includes Fordyce Marshall sold 14.22K, Fordyce Marshall sold 4.28K, Fordyce Marshall sold 14.13K, Fordyce Marshall sold 7.92K, and Fordyce Marshall sold 900. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for VERA?: Yes. Rallies tracks VERA insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is VERA research on Rallies investment advice?: No. Rallies provides research, data, and educational context for VERA. It does not provide personalized investment advice.